Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed No phase listed Observational Results available

Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy

ClinicalTrials.gov ID: NCT00791518

Public ClinicalTrials.gov record NCT00791518. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Evaluation of Lung Function and Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A multicenter study to evaluate lung function and symptoms in subjects with COPD who have been on regular use of only one long-acting bronchodilator.

Study identification

NCT ID
NCT00791518
Recruitment status
Completed
Study type
Observational
Phase
Not listed
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
1,084 participants

Conditions and interventions

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2008 (Type not available)
Primary completion
May 2009 (Actual)
Completion
May 2009 (Actual)
Last update posted
Jul 30, 2014

2008 – 2009

United States locations

U.S. sites
57
U.S. states
20
U.S. cities
54
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 25249 —
GSK Investigational Site Tucson Arizona 85741 —
GSK Investigational Site Little Rock Arkansas 72205 —
GSK Investigational Site National City California 91950 —
GSK Investigational Site Rancho Mirage California 92270 —
GSK Investigational Site Riverside California 92506 —
GSK Investigational Site Santa Ana California 92704 —
GSK Investigational Site Walnut Creek California 94598 —
GSK Investigational Site Colorado Springs Colorado 80907 —
GSK Investigational Site Colorado Springs Colorado 80909 —
GSK Investigational Site Stamford Connecticut 06902 —
GSK Investigational Site Cocoa Florida 32927 —
GSK Investigational Site DeLand Florida 32720 —
GSK Investigational Site Largo Florida 33770 —
GSK Investigational Site Miami Florida 33183 —
GSK Investigational Site Miami Florida 33186 —
GSK Investigational Site Naranja Florida 33032 —
GSK Investigational Site South Miami Florida 33143 —
GSK Investigational Site Tamarac Florida 33321 —
GSK Investigational Site Tampa Florida 33613 —
GSK Investigational Site Winter Park Florida 32789 —
GSK Investigational Site Evansville Indiana 47711 —
GSK Investigational Site Indianapolis Indiana 46229 —
GSK Investigational Site New Orleans Louisiana 70115 —
GSK Investigational Site Sunset Louisiana 70584 —
GSK Investigational Site Biddeford Maine 04005 —
GSK Investigational Site Rochester Minnesota 55904 —
GSK Investigational Site Albany New York 12205 —
GSK Investigational Site Mooresville North Carolina 28117 —
GSK Investigational Site Raleigh North Carolina 27609 —
GSK Investigational Site Salisbury North Carolina 28144 —
GSK Investigational Site Wilmington North Carolina 28401 —
GSK Investigational Site Winston-Salem North Carolina 27103 —
GSK Investigational Site Canton Ohio 44718 —
GSK Investigational Site Cincinnati Ohio 45231 —
GSK Investigational Site Dayton Ohio 45439 —
GSK Investigational Site Oklahoma City Oklahoma 73112 —
GSK Investigational Site Oklahoma City Oklahoma 73120 —
GSK Investigational Site Portland Oregon 97213 —
GSK Investigational Site Clairton Pennsylvania 15205 —
GSK Investigational Site Pittsburgh Pennsylvania 15243 —
GSK Investigational Site Anderson South Carolina 29621 —
GSK Investigational Site Easley South Carolina 29650 —
GSK Investigational Site Gaffney South Carolina 29340 —
GSK Investigational Site Greenville South Carolina 29615 —
GSK Investigational Site Mt. Pleasant South Carolina 29464 —
GSK Investigational Site Spartanburg South Carolina 29303 —
GSK Investigational Site Union South Carolina 29379 —
GSK Investigational Site Johnson City Tennessee 37601 —
GSK Investigational Site Milan Tennessee 38358 —
GSK Investigational Site New Tazewell Tennessee 37824-1409 —
GSK Investigational Site Boerne Texas 78006 —
GSK Investigational Site Houston Texas 77054 —
GSK Investigational Site Killeen Texas 76542 —
GSK Investigational Site Plano Texas 75024 —
GSK Investigational Site Waco Texas 76712 —
GSK Investigational Site Wichita Falls Texas 76309 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00791518, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 30, 2014 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00791518 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →